ImmuneWalk Therapeutics

• 08/05/2025
• Seed
• $7,000,000

ImmuneWalk Therapeutics is a private clinical-stage company focused on development of novel therapies for chronic inflammatory diseases. Our Monocyte Targeting Technology (MTT) is designed to selectively block the migration (`walking`) of monocytes from the blood stream into inflamed tissues. Our lead candidate, IW-601, is a proprietary monoclonal antibody that is engineered to specifically prevent monocytes from exiting the blood stream and traveling to inflammatory sites. IW-601 is designed to offer a novel and differentiated approach in the landscape of current anti-inflammatory agents.
With clear disease-modifying activity in models of Multiple Sclerosis, Rheumatoid Arthritis, Inflammatory Bowel Disease and Non- Alcoholic Steatohepatitis, in addition to proof-of-concept from patient’s cells, we are advancing IW-601 to a Ph1 clinical trial.

---

---